TIL Therapy in Non-small-cell Lung Cancer (NSCLC) Patients

Aim of the study is to investigate the efficacy and safety of adoptive cell therapy (ACT) with tumor-infiltrating lymphocytes (TIL) in patients with advanced pre-treated non-small cell lung cancer (NSCLC).

Trial Details

NCT ID
NCT06455917
Phase
PHASE2
Sponsor
University Hospital, Basel, Switzerland
Status
RECRUITING
Cancer Type
Lung Cancer
Interventions
  • TILs（Tumor Infiltrating Lymphocytes）
Locations (sample)
  • Basel, Canton of Basel-City, Switzerland|47.55839,7.57327

Key Eligibility Criteria

  • Ability of the patient to understand the purpose of the study, provide signed and dated informed consent prior to performing any protocol-related p…
  • Age ≥ 18 years.
  • Eastern Cooperative Oncology Group (ECOG) Performance Status 0-1 (cf. Appendix).
  • Histologically confirmed NSCLC.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lung Cancer Trials on Trialify →